Trimetazidine: new French pharmacovigilance data.
The authors of a French pharmacovigilance study examined more than 300 adverse effects due to trimetazidine, reported up to the beginning of 2008. This study yielded useful information about the adverse effects of trimetazidine other than those already known: thrombocytopenia and extrapyramidal syndromes.